191 related articles for article (PubMed ID: 17704160)
1. Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
Malina J; Novakova O; Vojtiskova M; Natile G; Brabec V
Biophys J; 2007 Dec; 93(11):3950-62. PubMed ID: 17704160
[TBL] [Abstract][Full Text] [Related]
2. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
Wu Y; Bhattacharyya D; King CL; Baskerville-Abraham I; Huh SH; Boysen G; Swenberg JA; Temple B; Campbell SL; Chaney SG
Biochemistry; 2007 Jun; 46(22):6477-87. PubMed ID: 17497831
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
4. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
Kasparkova J; Vojtiskova M; Natile G; Brabec V
Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
[TBL] [Abstract][Full Text] [Related]
5. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex.
Wu Y; Pradhan P; Havener J; Boysen G; Swenberg JA; Campbell SL; Chaney SG
J Mol Biol; 2004 Aug; 341(5):1251-69. PubMed ID: 15321720
[TBL] [Abstract][Full Text] [Related]
6. 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex.
Spingler B; Whittington DA; Lippard SJ
Inorg Chem; 2001 Oct; 40(22):5596-602. PubMed ID: 11599959
[TBL] [Abstract][Full Text] [Related]
7. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
8. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
9. 1,2-GG intrastrand cross-link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross-link of conventional cisplatin.
Moriarity B; Nováková O; Farrell N; Brabec V; Kaspárková J
Arch Biochem Biophys; 2007 Mar; 459(2):264-72. PubMed ID: 17224122
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.
Scheeff ED; Briggs JM; Howell SB
Mol Pharmacol; 1999 Sep; 56(3):633-43. PubMed ID: 10462551
[TBL] [Abstract][Full Text] [Related]
11. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
[TBL] [Abstract][Full Text] [Related]
12. Molecular interaction of DNA with bisplatinum(II) complexes having bis(vicinal 1,2-diamines) as ligand.
Büning H; Altman J; Beck W; Zorbas H
Biochemistry; 1997 Sep; 36(38):11408-18. PubMed ID: 9298960
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the sequence-dependent effects of platinum-DNA adducts.
Ramachandran S; Temple BR; Chaney SG; Dokholyan NV
Nucleic Acids Res; 2009 May; 37(8):2434-48. PubMed ID: 19255091
[TBL] [Abstract][Full Text] [Related]
14. Fast interstrand cross-linking of cisplatin-DNA monoadducts compared with intrastrand chelation: a kinetic study using hairpin-stabilized duplex oligonucleotides.
Monjardet-Bas V; Chottard JC; Kozelka J
Chemistry; 2002 Mar; 8(5):1144-50. PubMed ID: 11891902
[TBL] [Abstract][Full Text] [Related]
15. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin adducts on a GGG sequence within a DNA duplex studied by NMR spectroscopy and molecular dynamics simulations.
Téletchéa S; Skauge T; Sletten E; Kozelka J
Chemistry; 2009 Nov; 15(45):12320-37. PubMed ID: 19813235
[TBL] [Abstract][Full Text] [Related]
17. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
18. Translesion DNA synthesis across double-base lesions derived from cross-links of an antitumor trinuclear platinum compound: primer extension, conformational and thermodynamic studies.
Novakova O; Farrell NP; Brabec V
Metallomics; 2018 Jan; 10(1):132-144. PubMed ID: 29242879
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.
Sharma S; Gong P; Temple B; Bhattacharyya D; Dokholyan NV; Chaney SG
J Mol Biol; 2007 Nov; 373(5):1123-40. PubMed ID: 17900616
[TBL] [Abstract][Full Text] [Related]
20. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
